BioVie Inc. Income Tax Examination, Penalties and Interest Expense
BioVie Inc. (BIVI) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-08-13
- BioVie Inc. income tax examination, penalties and interest expense for fiscal 2026 was $0.00.
- BioVie Inc. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- BioVie Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- BioVie Inc. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2026-06-30 | $0.00 10-K · filed 2026-08-13 |
| 2025-06-30 | $0.00 10-K · filed 2026-08-13 |
| 2023-06-30 | $0.00 10-K · filed 2023-08-16 |
| 2022-06-30 | $0.00 10-K · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |